Intravenous versus subcutaneous immunoglobulin in patients with haematological malignancies: time-driven activity-based costing

Our results indicated higher annual direct costs per patient treated with SCIg than IVIg, despite higher in-hospital costs associated with IVIg administration. Further research, including understanding costs to patients, is warranted.